Intelligence Feed event · Equity · 2026-09-25

    ADARx Pharmaceuticals Prices Upsized $446.3M Initial Public Offering at $17

    Question

    ADARx Pharmaceuticals Prices Upsized $446.3M Initial Public Offering at $17

    Direct answer

    ADARx Pharmaceuticals priced an expanded initial public offering of 26.25 million shares at $17.00 each, raising $446.3 million in gross proceeds. The company develops clinical-stage siRNA therapeutic candidates. The stock opens for trading on the Nasdaq on September 25, 2026 under ticker ADRX, providing fresh liquidity sentiment data for the healthcare equity capital markets window.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-25
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “ADARx Pharmaceuticals Prices Upsized $446.3M Initial Public Offering at $17”, revision 1, evidence through 2026-09-25. https://marketontology.com/market-events/2026-09-25/adarx-pharmaceuticals-prices-upsized-446-3m-initial-public-offering-at-17-eaf779

    EQUITY
    ADARx Pharmaceuticals Prices Upsized $446.3M Initial Public Offering at $17
    ADARx Pharmaceuticals priced an expanded initial public offering of 26.25 million shares at $17.00 each, raising $446.3 million in gross proceeds. The company develops clinical-stage siRNA therapeutic candidates. The stock opens for trading on the Nasdaq on September 25, 2026 under ticker ADRX, providing fresh liquidity sentiment data for the healthcare equity capital markets window.
    ADRX
    Impact
    69
    SEP 25
    SIG
    90%
    ADRX
    ADARx Pharmaceuticals Prices Upsized $446.3M Initial Public Offering at $17
    ADARx Pharmaceuticals priced an expanded initial public offering of 26.25 million shares at $17.00 each, raising $446.3 million in gross proceeds. The company develops clinical-stage siRNA therapeutic candidates. The stock opens for trading on the Nasdaq on September 25, 2026 under ticker ADRX, providing fresh liquidity sentiment data for the healthcare equity capital markets window.
    → Capital inflow of $446.3M funds clinical pipeline execution while testing public biotech equity market liquidity.
    Impact
    ADARx Pharmaceuticals priced an expanded initial public offering of 26.25 million shares at $17.00 each, raising $446.3 million in gross proceeds. The company develops clinical-stage siRNA therapeutic candidates. The stock opens for trading on the Nasdaq on September 25, 2026 under ticker ADRX, providing fresh liquidity sentiment data for the healthcare equity capital markets window.
    Affected
    ADRX
    Transmission
    Capital inflow of $446.3M funds clinical pipeline execution while testing public biotech equity market liquidity.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    ADRXfirst-day trading liquidity and IPO capitalizationUpintradayPriced 26.25M shares at $17/share to raise $446.3M gross proceeds.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    ADRXUpdisagreed19.35 2026-09-25+3.82%-5.68%Pending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month